Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: What is the optimal level of testosterone?

European Urology, Supplements

Volumn 4, Issue 5, 2005, Pages 14-19

  Tombal, B ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Acute on chronic response; Breakthrough response; Castration level; Hormonal escape; LHRH agonists; Prostate cancer; Review; Testosterone

Indexed keywords

ESTROGEN; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN;

CANCER HORMONE THERAPY; CASTRATION; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG RESPONSE; HOT FLUSH; HUMAN; IMPOTENCE; LIBIDO DISORDER; MALE; MEDLINE; ORCHIECTOMY; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; THROMBOEMBOLISM; TREATMENT FAILURE;

EID: 20344374658     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2005.04.004     Document Type: Article

References (29)

1. D.P. Byar, and D.K. Corle Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies NCI Monogr 7 1988 165 170
2. A.V. Schally, A.J. Kastin, and A. Arimura Hypothalamic FSH and LH-regulating hormone. Structure, physiology and clinical studies Fertil Steril 22 1971 703 721
3. The Leuprolide Study Group Leuprolide versus diethylstilbestrol for metastatic prostate cancer N Engl J Med 311 1984 1281 1286
4. P. Mongiat-Artus, and P. Teillac Role of luteinising hormone releasing hormone (LHRH) agonists in the management of prostate cancer Eur Urol Suppl 4 5 2005 4 13
5. M.G. Oefelein, and M.I. Resnick Effective testosterone suppression for patients with prostate cancer: is there a best castration? Urology 62 2 2003 207 213
6. R. Sharifi, R. Browneller Leuprolide Study Group Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer J Urol 168 3 2002 1001 1004
7. W.P. Jordan, C.E. Blackard, and D.P. Byar Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma South Med J 70 1977 1411 1413
8. M.G. Oefelein, A. Feng, M.J. Scolieri, D. Ricchiutti, and M.I. Resnick Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making Urology 56 6 2000 1021 1024
9. T.J. Wilke, and D.J. Utley Total testosterone, free-androgen index, calculated free testosterone, and free testosterone by analog RIA compared in hirsute women and in otherwise-normal women with altered binding of sex-hormone-binding globulin Clin Chem 33 8 1987 1372 1375
10. M.J. Wheeler, A. D'Souza, J. Matadeen, and P. Croos Ciba Corning ACS:180 testosterone assay evaluated Clin Chem. 42 9 1996 1445 1449
11. A.V. Zherdev, N.A. Byzova, V.A. Izumrudov, and B.B. Dzantiev Rapid polyelectrolyte-based immunofiltration technique for testosterone detection in serum samples Analyst 128 10 2003 1275 1280
12. A.V. Kaisary, C.J. Tyrrell, W.B. Peeling, and K. Griffiths Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma Br J Urol 67 5 1991 502 508
13. H.F. Rohl, and H.P. Beuke Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer Scand J Urol Nephrol 26 1 1992 11 14
14. B.J. Lin, K.K. Chen, M.T. Chen, and L.S. Chang The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer Urology 43 6 1994 834 837
15. N.J. Vogelzang, G.W. Chodak, M.S. Soloway, N.L. Block, P.F. Schellhammer, J.A. Smith Jr. Zoladex Prostate Study Group Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial Urology 46 2 1995 220 226
16. M.G. Oefelein, and R. Cornum Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm J Urol 164 3 Pt 1 2000 726 729
17. R. Perez-Marreno, F.M. Chu, D. Gleason, E. Loizides, B. Wachs, and R.C. Tyler A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer Clin Ther 24 11 2002 1902 1914
18. F.M. Chu, M. Jayson, M.K. Dineen, R. Perez, R. Harkaway, and R.C. Tyler A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer J Urol 168 3 2002 1199 1203
19. O. Sartor, M.K. Dineen, R. Perez-Marreno, F.M. Chu, G.J. Carron, and R.C. Tyler An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer Urology 62 2 2003 319 323
20. J. Kawakami, and A. Morales A comprehensive hormonal evaluation in patients with cancer of the prostate on androgen supression with LHRH agonists J Urol 167 Suppl. 4 2002 288 (abs. 1135)
21. M.F. Sarosdy, P.F. Schellhammer, M.S. Soloway, N.J. Vogelzang, E.D. Crawford, and J. Presti Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer BJU Int 83 7 1999 801 806
22. D. Jocham Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results Urol Int 60 Suppl 2 1998 18 24
23. M.S. Khan, and A. O'Brien An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate Urol Int 60 1 1998 33 40
24. N.R. Zinner, M. Bidair, A. Centeno, and K. Tomera Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial Urology 64 6 2004 1177 1181
25. M.G. Oefelein Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration J Urol 160 5 1998 1685 1688
26. M.G. Oefelein Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment Urology 54 4 1999 694 699
27. M.G. Oefelein Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer J Urol 169 1 2003 251 255
28. M.C. Hall, R.J. Fritzsch, A.I. Sagalowsky, A. Ahrens, B. Petty, and C.G. Roehrborn Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer Urology 53 5 1999 898 902
29. D. McLeod, N. Zinner, K. Tomera, D. Gleason, N. Fotheringham, M. Campion Abarelix Study Group A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer Urology 58 5 2001 756 761